Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy

(2022) Sander C. Ebbers et al.   EJNMMI Research

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis

(2022) Mohamad Bassam Sonbol et al.   ONCOLOGIST

Intra-arterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients

(2021) Evert-Jan P.A. Vonken et al.   JOURNAL OF NUCLEAR MEDICINE

Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease

(2021) Parul Thakral et al.   BRITISH JOURNAL OF RADIOLOGY

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

(2020) Jonathan Strosberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study

(2020) Arthur J A T Braat et al.   LANCET ONCOLOGY

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

(2020) Sander C. Ebbers et al.   Trials

Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors

(2020) Courtney Lawhn-Heath et al.   JOURNAL OF NUCLEAR MEDICINE

Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease

(2020) Rahul V. Parghane et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

(2017) Rodney J. Hicks et al.   NEUROENDOCRINOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liver Metastases of Small Intestine Neuroendocrine Tumors

(2015) Chanjuan Shi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

[111In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy

(2014) Stefan E. Pool et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Recommendations for management of patients with neuroendocrine liver metastases

(2014) Andrea Frilling et al.   LANCET ONCOLOGY

Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours

(2013) C Lepage et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver

(2011) Zhaohai Yang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Intraarterial Treatment of GEP NET: 68Ga-DOTATOC SUV Cannot Predict 90Y-DOTATOC Uptake

(2011) C. Brogsitter et al.   CLINICAL CANCER RESEARCH

Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

(2011) Clemens Kratochwil et al.   ENDOCRINE-RELATED CANCER

Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2010) C. Kratochwil et al.   CLINICAL CANCER RESEARCH

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

(2010) Martin B Niederle et al.   ENDOCRINE-RELATED CANCER

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

(2010) Irina Velikyan et al.   NUCLEAR MEDICINE AND BIOLOGY

Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues

(2009) B. Waser et al.   JOURNAL OF NUCLEAR MEDICINE

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY